These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 35639847)

  • 1. [The role of molecular genetic factors in the development of cholangiocellular carcinoma].
    Chulkova SV; Loginov VI; Podluzhnyi DV; Egorova AV; Syskova AY; Semichev DG; Gladilina IA; Kudashkin NE
    Arkh Patol; 2022; 84(3):76-83. PubMed ID: 35639847
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Promoter methylation profiles of tumor suppressor genes in intrahepatic and extrahepatic cholangiocarcinoma.
    Yang B; House MG; Guo M; Herman JG; Clark DP
    Mod Pathol; 2005 Mar; 18(3):412-20. PubMed ID: 15467712
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Morphological subclassification of intrahepatic cholangiocarcinoma: etiological, clinicopathological, and molecular features.
    Liau JY; Tsai JH; Yuan RH; Chang CN; Lee HJ; Jeng YM
    Mod Pathol; 2014 Aug; 27(8):1163-73. PubMed ID: 24406866
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The pathways of genetic transformation in cholangiocarcinogenesis.
    Serafini FM; Radvinsky D
    Cancer Genet; 2016 Dec; 209(12):554-558. PubMed ID: 27720541
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Methylation profiles of multiple CpG island loci in extrahepatic cholangiocarcinoma versus those of intrahepatic cholangiocarcinomas.
    Kim BH; Cho NY; Choi M; Lee S; Jang JJ; Kang GH
    Arch Pathol Lab Med; 2007 Jun; 131(6):923-30. PubMed ID: 17550320
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genetic and molecular abnormalities in cholangiocarcinogenesis.
    Hassid VJ; Orlando FA; Awad ZT; Tan D; Khoury T; Ahmed BH; Alrawi SJ
    Anticancer Res; 2009 Apr; 29(4):1151-6. PubMed ID: 19414358
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cholangiocarcinoma.
    Krasinskas AM
    Surg Pathol Clin; 2018 Jun; 11(2):403-429. PubMed ID: 29751883
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anatomical, histomorphological and molecular classification of cholangiocarcinoma.
    Kendall T; Verheij J; Gaudio E; Evert M; Guido M; Goeppert B; Carpino G
    Liver Int; 2019 May; 39 Suppl 1():7-18. PubMed ID: 30882996
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cholangiocarcinoma: new insights into disease pathogenesis and biology.
    Braconi C; Patel T
    Infect Dis Clin North Am; 2010 Dec; 24(4):871-84, vii. PubMed ID: 20937455
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pathogenesis of cholangiocarcinoma: From genetics to signalling pathways.
    Kongpetch S; Jusakul A; Ong CK; Lim WK; Rozen SG; Tan P; Teh BT
    Best Pract Res Clin Gastroenterol; 2015 Apr; 29(2):233-44. PubMed ID: 25966424
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Global alterations of DNA methylation in cholangiocarcinoma target the Wnt signaling pathway.
    Goeppert B; Konermann C; Schmidt CR; Bogatyrova O; Geiselhart L; Ernst C; Gu L; Becker N; Zucknick M; Mehrabi A; Hafezi M; Klauschen F; Stenzinger A; Warth A; Breuhahn K; Renner M; Weichert W; Schirmacher P; Plass C; Weichenhan D
    Hepatology; 2014 Feb; 59(2):544-54. PubMed ID: 24002901
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Integrative analysis reveals early and distinct genetic and epigenetic changes in intraductal papillary and tubulopapillary cholangiocarcinogenesis.
    Goeppert B; Stichel D; Toth R; Fritzsche S; Loeffler MA; Schlitter AM; Neumann O; Assenov Y; Vogel MN; Mehrabi A; Hoffmann K; Köhler B; Springfeld C; Weichenhan D; Plass C; Esposito I; Schirmacher P; von Deimling A; Roessler S
    Gut; 2022 Feb; 71(2):391-401. PubMed ID: 33468537
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Gallbladder and bile duct carcinoma. Biology and pathology].
    Tannapfel A; Wittekind C
    Internist (Berl); 2004 Jan; 45(1):33-41. PubMed ID: 14735242
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Molecular profiling in daily practice for cholangiocarcinoma].
    Selves J
    Ann Pathol; 2022 Dec; 42(6S):6S5-6S7. PubMed ID: 36577541
    [No Abstract]   [Full Text] [Related]  

  • 15. Correlation between promoter methylation of p14(ARF), TMS1/ASC, and DAPK, and p53 mutation with prognosis in cholangiocarcinoma.
    Xiaofang L; Kun T; Shaoping Y; Zaiqiu W; Hailong S
    World J Surg Oncol; 2012 Jan; 10():5. PubMed ID: 22230750
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Promoter hypermethylation of death-associated protein kinase gene in cholangiocarcinoma.
    Liu XF; Kong FM; Xu Z; Yu SP; Sun FB; Zhang CS; Huang QX; Zhou XT; Song ZW
    Hepatobiliary Pancreat Dis Int; 2007 Aug; 6(4):407-11. PubMed ID: 17690039
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fibroblast growth factor receptor 2 translocations in intrahepatic cholangiocarcinoma.
    Graham RP; Barr Fritcher EG; Pestova E; Schulz J; Sitailo LA; Vasmatzis G; Murphy SJ; McWilliams RR; Hart SN; Halling KC; Roberts LR; Gores GJ; Couch FJ; Zhang L; Borad MJ; Kipp BR
    Hum Pathol; 2014 Aug; 45(8):1630-8. PubMed ID: 24837095
    [TBL] [Abstract][Full Text] [Related]  

  • 18. DLEC1 methylation is associated with a better clinical outcome in patients with intrahepatic cholangiocarcinoma of the small duct subtype.
    Kim Y; Lee K; Jeong S; Wen X; Cho NY; Kang GH
    Virchows Arch; 2019 Jul; 475(1):49-58. PubMed ID: 30610381
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The roles of epigenetic regulation in cholangiocarcinogenesis.
    Zhong B; Liao Q; Wang X; Wang X; Zhang J
    Biomed Pharmacother; 2023 Oct; 166():115290. PubMed ID: 37557012
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of epigenetic alterations in cholangiocarcinoma.
    Tischoff I; Wittekind C; Tannapfel A
    J Hepatobiliary Pancreat Surg; 2006; 13(4):274-9. PubMed ID: 16858537
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.